Recent Investment Analysts’ Ratings Updates for AbbVie (ABBV)

A number of research firms have changed their ratings and price targets for AbbVie (NYSE: ABBV):

• 2/3/2025 – AbbVie had its price target raised by analysts at Wells Fargo & Company from $195.00 to $210.00. They now have an “overweight” rating on the stock.
• 2/3/2025 – AbbVie had its price target raised by analysts at Morgan Stanley from $224.00 to $239.00. They now have an “overweight” rating on the stock.
• 2/3/2025 – AbbVie had its “outperform” rating reaffirmed by analysts at Raymond James. They now have a $220.00 price target on the stock, up previously from $218.00.
• 2/3/2025 – AbbVie had its price target raised by analysts at BMO Capital Markets from $208.00 to $215.00. They now have an “outperform” rating on the stock.
• 2/3/2025 – AbbVie had its price target raised by analysts at UBS Group AG from $181.00 to $190.00. They now have a “neutral” rating on the stock.
• 2/3/2025 – AbbVie had its price target raised by analysts at Citigroup Inc. from $205.00 to $215.00. They now have a “buy” rating on the stock.
• 2/3/2025 – AbbVie had its price target raised by analysts at Truist Financial Co. from $211.00 to $217.00. They now have a “buy” rating on the stock.
• 2/3/2025 – AbbVie had its price target raised by analysts at Guggenheim from $212.00 to $214.00. They now have a “buy” rating on the stock.
• 1/28/2025 – AbbVie had its price target lowered by analysts at Citigroup Inc. from $215.00 to $205.00. They now have a “buy” rating on the stock.
• 1/8/2025 – AbbVie had its price target lowered by analysts at Truist Financial Co. from $215.00 to $211.00. They now have a “buy” rating on the stock.
• 12/17/2024 – AbbVie had its “overweight” rating reaffirmed by analysts at Piper Sandler Companies. They now have a $220.00 price target on the stock.
• 12/17/2024 – AbbVie had its price target raised by analysts at Piper Sandler from $212.00 to $220.00. They now have an “overweight” rating on the stock.
• 12/10/2024 – AbbVie had its “neutral” rating reaffirmed by analysts at Bank of America Co.. They now have a $191.00 price target on the stock.

AbbVie Stock Performance

NYSE:ABBV opened at $189.97 on Wednesday. The company has a fifty day moving average of $176.84 and a two-hundred day moving average of $185.26. AbbVie Inc. has a fifty-two week low of $153.58 and a fifty-two week high of $207.32. The stock has a market capitalization of $335.71 billion, a PE ratio of 79.16, a P/E/G ratio of 1.84 and a beta of 0.58. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 257.91%. During the same period in the previous year, the company posted $2.79 earnings per share. As a group, research analysts forecast that AbbVie Inc. will post 12.26 earnings per share for the current fiscal year.

Insider Activity

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the transaction, the senior vice president now directly owns 6,983 shares of the company’s stock, valued at $1,202,751.92. The trade was a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.25% of the company’s stock.

Hedge Funds Weigh In On AbbVie

A number of hedge funds have recently modified their holdings of the business. RPg Family Wealth Advisory LLC acquired a new position in AbbVie during the third quarter worth $28,000. Fiduciary Advisors Inc. acquired a new position in AbbVie during the 4th quarter worth about $29,000. Bradley & Co. Private Wealth Management LLC purchased a new position in AbbVie during the 4th quarter valued at about $31,000. Retirement Wealth Solutions LLC acquired a new position in AbbVie in the 4th quarter valued at about $35,000. Finally, Marquette Asset Management LLC purchased a new stake in AbbVie during the third quarter worth about $39,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.